Allied-Bristol Life Sciences Licenses Platform Technology And Lead Molecules From Yale University

BOSTON--(BUSINESS WIRE)--Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned between Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY), announced that it has entered into a worldwide licensing agreement with Yale University for a proprietary platform technology and associated lead molecules that will be further developed to treat diseases such as prostate cancer, a leading cause of cancer-related deaths among American men.

Help employers find you! Check out all the jobs and post your resume.